Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer.

[1]  C. Temm,et al.  Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs , 2017, Basic Research in Cardiology.

[2]  J. M. Bradshaw,et al.  Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. , 2017, Journal of medicinal chemistry.

[3]  Melissa R. Miller,et al.  Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels. , 2017, Journal of medicinal chemistry.

[4]  P. Camparo,et al.  Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation. , 2017, Cancer research.

[5]  T. Rodrigues,et al.  Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents. , 2016, Chemical Society reviews.

[6]  A. Rak,et al.  Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844). , 2016, Journal of medicinal chemistry.

[7]  Jingwei Tian,et al.  Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo , 2016, Acta pharmaceutica Sinica. B.

[8]  F. Lordick,et al.  Clinical impact of tumour biology in the management of gastroesophageal cancer , 2016, Nature Reviews Clinical Oncology.

[9]  R. Preissner,et al.  TRPC6 G757D Loss-of-Function Mutation Associates with FSGS. , 2016, Journal of the American Society of Nephrology : JASN.

[10]  Wenting Xu,et al.  Molecular targeted therapy for the treatment of gastric cancer , 2016, Journal of Experimental & Clinical Cancer Research.

[11]  W. Kuebler,et al.  Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor , 2016, Molecular Pharmacology.

[12]  Yizheng Wang,et al.  TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production , 2015, Nature Communications.

[13]  Meng Wu,et al.  Identification and optimization of 2‐aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels , 2015, British journal of pharmacology.

[14]  G. Hessler,et al.  Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol‐sensitive TRPC cation channels , 2015, British journal of pharmacology.

[15]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[16]  Zhijia Wang,et al.  Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. , 2015, Journal of medicinal chemistry.

[17]  G. Du,et al.  Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome , 2014, PloS one.

[18]  D. Kass,et al.  Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy , 2014, Proceedings of the National Academy of Sciences.

[19]  D. Mobley,et al.  Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. , 2013, Journal of medicinal chemistry.

[20]  D. Holt,et al.  The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore. , 2013, Bioorganic & Medicinal Chemistry Letters.

[21]  C. Romanin,et al.  Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca2+ entry pathways , 2012, British journal of pharmacology.

[22]  W. Kuebler,et al.  Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction. , 2012, Cell calcium.

[23]  T. Taniguchi,et al.  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. , 2011, Journal of medicinal chemistry.

[24]  Melissa R. Miller,et al.  Identification of ML204, a Novel Potent Antagonist That Selectively Modulates Native TRPC4/C5 Ion Channels* , 2011, The Journal of Biological Chemistry.

[25]  Yizheng Wang,et al.  Targeting TRPC6 channels in oesophageal carcinoma growth , 2010, Expert opinion on therapeutic targets.

[26]  Kechun Zhou,et al.  Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells , 2009, International journal of cancer.

[27]  M. Freichel,et al.  Deletion of TRPC4 and TRPC6 in mice impairs smooth muscle contraction and intestinal motility in vivo. , 2009, Gastroenterology.

[28]  Kechun Zhou,et al.  Critical role of TRPC6 channels in VEGF-mediated angiogenesis. , 2009, Cancer letters.

[29]  Kechun Zhou,et al.  Transient receptor potential channel C3 contributes to the progression of human ovarian cancer , 2009, Oncogene.

[30]  미헤 주잔네,et al.  Use of norgestimate as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels , 2008 .

[31]  M. Nishida,et al.  TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy , 2006, The EMBO journal.

[32]  D. Clapham,et al.  TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function , 2005, Nature Genetics.

[33]  M. Pericak-Vance,et al.  A Mutation in the TRPC6 Cation Channel Causes Familial Focal Segmental Glomerulosclerosis , 2005, Science.

[34]  M. Nowycky,et al.  TRPC5 activation kinetics are modulated by the scaffolding protein ezrin/radixin/moesin‐binding phosphoprotein‐50 (EBP50) , 2004, Journal of cellular physiology.

[35]  I. Fantozzi,et al.  Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Tse,et al.  Chronic Hypoxia–Induced Upregulation of Store-Operated and Receptor-Operated Ca2 Channels in Pulmonary Arterial Smooth Muscle Cells: A Novel Mechanism of Hypoxic Pulmonary Hypertension , 2004, Circulation research.

[37]  Bernd Nilius,et al.  The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels , 2004, Nature.

[38]  Chi-Hung Lin,et al.  Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. , 2003, Journal of medicinal chemistry.

[39]  T. Gudermann,et al.  TRPC6: physiological function and pathophysiological relevance. , 2014, Handbook of experimental pharmacology.

[40]  R. Labianca,et al.  Gastric cancer. , 2005, Critical reviews in oncology/hematology.